公开(公告)号：EP1311503A1

公开(公告)日：2003-05-21

申请号：EP01969491.8

申请日：2001-07-24

申请人： MERCK PATENT GmbH

发明人： GOTTSCHLICH, Rudolf ,  ACKERMANN, Karl-August ,  PRÜCHER, Helmut ,  SEYFRIED, Christoph ,  BARTOSZYK, Gert ,  VAN AMSTERDAM, Christoph

IPC分类号： C07D405/14 ,  A61P25/18

CPC分类号： C07D405/12

摘要： The invention relates to novel chromenone derivatives of formula (I), wherein Y, X, R?1, R2, R3¿ and n have one of the meanings cited in Patent Claim No. 1, serving as inhibitors of the 5-HT¿1A? receptor and of the dopamine D2 receptor.

公开(公告)号：EP1228041A2

公开(公告)日：2002-08-07

申请号：EP00954447.9

申请日：2000-07-07

申请人： MERCK PATENT GmbH

发明人： BÖTTCHER, Henning ,  MÄRZ, Joachim ,  GREINER, Hartmut ,  HARTING, Jürgen ,  BARTOSZYK, Gerd ,  SEYFRIED, Christoph ,  VAN AMSTERDAM, Christoph

IPC分类号： C07D209/12 ,  A61K31/404 ,  A61P43/00 ,  C07D403/06 ,  C07D409/06

CPC分类号： C07D209/12

摘要： The invention relates to compounds of formula (I), wherein R?1 and R3¿ have the meaning given in Claim 1. Said compounds are potent 5-HT¿2A?-antagonists and are suitable for the treatment of psychosis, schizophrenia, depression, neurological disorders, memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, eating disorders, e.g. nervous bulimia and anorexia, and premenstrual syndrome and/or for positively influencing compulsive behaviours (obsessive-compulsive disorder, OCD).

公开(公告)号：EP1202966A1

公开(公告)日：2002-05-08

申请号：EP00964004.6

申请日：2000-08-08

申请人： MERCK PATENT GmbH

发明人： PRÜCHER, Helmut ,  BÖTTCHER, Henning ,  ACKERMANN, Karl-August ,  GOTTSCHLICH, Rudolf ,  GREINER, Hartmut ,  HARTING, Jürgen ,  BARTOSZYK, Gerd ,  SEYFRIED, Christoph ,  VAN AMSTERDAM, Christoph

IPC分类号： C07D211/18 ,  C07D409/06 ,  C07D405/06 ,  C07D417/06 ,  C07D401/06 ,  A61K31/445 ,  A61K31/4523 ,  A61P25/00 ,  A61P25/16 ,  A61P25/18

CPC分类号： C07D401/06 ,  C07D211/22 ,  C07D405/06 ,  C07D409/06 ,  C07D417/06

摘要： The invention relates to compounds of formula (I), wherein R1, R2 and A have the meanings given in claim 1, are potent 5-HT¿2A? antagonists and are suitable for treating psychoses, schizophrenia, depression, neurological disorders, impaired memory, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, eating disorders such as bulimia and anorexia nervosa, Pre-Menstrual Syndrome and/or for positively influencing obsessive-compulsive disorders, (OCD).

摘要翻译： 本发明涉及式（I）的化合物，其中R1，R2和A具有权利要求1中给出的含义，是有效的5-HT2A 拮抗剂，适用于治疗精神病，精神分裂症，抑郁症，神经疾病，记忆障碍，帕金森病，肌萎缩侧索硬化症，阿尔茨海默氏病，亨廷顿舞蹈病，食欲紊乱如神经性贪食症和神经性厌食症，月经前期综合征和/ 强迫症（OCD）。

公开(公告)号：EP1185272A2

公开(公告)日：2002-03-13

申请号：EP00935031.5

申请日：2000-05-16

申请人： MERCK PATENT GmbH

发明人： BARTOSZYK, Gerd ,  SEYFRIED, Christoph ,  VAN AMSTERDAM, Christoph ,  BÖTTCHER, Henning ,  SEDMAN, Ewen

IPC分类号： A61K31/495

CPC分类号： A61K31/496 ,  A61K31/00 ,  A61K31/495 ,  A61K31/497

摘要： 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof is used for the manufacture of a medicament for the treatment of sub-type anxiety disorders chosen from the sub-types panic disorder with or without agoraphobia, agoraphobia, obsessive-compulsive spectrum disorders, social phobia, posttraumatic stress disorder, acute stress indication or generalized-anxiety disorder, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, anorexia and fibromyalgia. A preferred salt is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.